Abstract: The instant disclosure provides antibodies that specifically bind to T-cell immunoreceptor with Ig and ITIM domains (TIGIT) (e.g., human TIGIT) and antagonize TIGIT function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Abstract: Antibodies that specifically bind to TIM 3 and antagonize TIM-3 function pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Abstract: A head-mounted display includes a front having a display housing and a back having a rear housing. A first member extends between the front and the back and is adjustable via an actuation of a first rotatable actuator and a first cabling mechanism. A second member extends between the front and the back and is adjustable via an actuation of a second rotatable actuator and a second cabling mechanism. A third member extends between the front and the back and is adjustable via the actuation of the second rotatable actuator and a third cabling mechanism.

Abstract: The instant disclosure provides antibodies that specifically bind to CTLA-4 (e.g., human CTLA-4) and antagonize CTLA-4 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Abstract: A head-mounted display (HMD) includes various features that allow for customizing the HMD to different users. The HMD may include an interpupillary distance (IPD) adjustment mechanism that includes a double biasing assembly for smooth, controlled adjustment of the spacing between lens tubes. The HMD may include a field of view (FOV) adjustment mechanism that includes first and second gear assemblies connected via a connecting rod to allow uniform adjustment of the spacing between the lenses and the user's face. The HMD may further include a swappable face gasket, a swappable visor, a removable head strap, and a modular accessory compartment for further customizations to the HMD. The HMD may further include inconspicuous spectrum-transmissive windows that are made with a spectrum-transmissive base material for the HMD housing that is coated with a spectrum-opaque material, and the spectrum-opaque material is selectively removed to create the spectrum-transmissive windows.

Abstract: A head-mounted display (HMD) includes various features that allow for customizing the HMD to different users. The HMD may include an interpupillary distance (IPD) adjustment mechanism that includes a double biasing assembly for smooth, controlled adjustment of the spacing between lens tubes. The HMD may include a field of view (FOV) adjustment mechanism that includes first and second gear assemblies connected via a connecting rod to allow uniform adjustment of the spacing between the lenses and the user's face. The HMD may further include a swappable face gasket, a swappable visor, a removable head strap, and a modular accessory compartment for further customizations to the HMD. The HMD may further include inconspicuous spectrum-transmissive windows that are made with a spectrum-transmissive base material for the HMD housing that is coated with a spectrum-opaque material, and the spectrum-opaque material is selectively removed to create the spectrum-transmissive windows.

Abstract: Provided are novel antigenic polypeptides comprising tumor-associated peptides, and compositions comprising the same. Such antigenic polypeptides and compositions are particularly useful as immunotherapeutics (e.g., cancer vaccines). Also provided are methods of inducing a cellular immune response using the polypeptides and compositions, methods of treating a disease using the polypeptides and compositions, kits comprising the polypeptides and compositions, methods of making the compositions, and antibodies and T cell receptors that specifically bind to the polypeptides.

Abstract: The instant disclosure provides antibodies that specifically bind to CD137 (e.g., human CD137) and increases CD137 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Abstract: There is described a securing device (10) for releasably securing a first object to a second objection. The device comprises a casing (12) and a coupling magnet (22) housed in the casing. The casing is configured for being inserted in a passageway formed by aligned openings (54, 60) of the first and second objects when assembled together, for blocking separation of the first object and the second object from one another. The coupling magnet (22) is moveable from an initial position to a working position to form a magnetic coupling for holding the casing in the passageway. The first and second objects can respectively be a tooth (50) of a mining or excavation bucket and an adaptor (52) of the bucket for the tooth (50). A fixed magnet (28) can be provided in the casing (12), the fixed magnet (28) being oppositely poled with respect to the coupling magnet (22) for damping the movement of the coupling magnet to its working position.

Abstract: A head-mounted display includes a front having a display housing and a back having a rear housing. A first member extends between the front and the back and is adjustable via an actuation of a first rotatable actuator and a first cabling mechanism. A second member extends between the front and the back and is adjustable via an actuation of a second rotatable actuator and a second cabling mechanism. A third member extends between the front and the back and is adjustable via the actuation of the second rotatable actuator and a third cabling mechanism.

Abstract: The instant disclosure provides antibodies that specifically bind to CD137 (e.g., human CD137) and increases CD137 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Abstract: The instant disclosure provides antibodies that specifically bind to T-cell immunoreceptor with Ig and ITIM domains (TIGIT) (e.g., human TIGIT) and antagonize TIGIT function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Abstract: The instant disclosure provides antibodies that specifically bind to CD137 (e.g., human CD137) and increases CD137 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Abstract: The present disclosure relates to a process for the processing of perfluoropolymer materials, and to the use of the resultant products in different potential applications, such as in the medical device field. The process can include, for example, the steps of: (i) dissolving one or more uncured perfluoropolymer materials in a solvent containing one or more liquid perfluorinated solvent(s) to form a solution; (ii) optionally adding one or more porogens and/or one or more functional additives to the solution formed in (i) to form a mixture; (iii) applying the resultant solution or mixture formed in steps (i) and (ii) to a substrate to form one or more partial or continuous deposited layers on the substrate; (iv) curing the perfluoropolymer within the deposited layer to form a perfluoroelastomeric product; and (v) optionally removing the porogen from the perfluoroelastomeric product.

Abstract: The instant disclosure provides antibodies that specifically bind to CD137 (e.g., human CD137) and increases CD137 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Abstract: The instant disclosure provides antibodies that specifically bind to TIM-3 (e.g., human TIM-3) and antagonize TIM-3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Abstract: The instant disclosure provides antibodies that specifically bind to CTLA-4 (e.g., human CTLA-4) and antagonize CTLA-4 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Abstract: The instant disclosure provides antibodies that specifically bind to T-cell immunoreceptor with Ig and ITIM domains (TIGIT) (e.g., human TIGIT) and antagonize TIGIT function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Abstract: The instant disclosure provides antibodies that specifically bind to CTLA-4 (e.g., human CTLA-4) and antagonize CTLA-4 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Abstract: The instant disclosure provides antibodies that specifically bind to CD137 (e.g., human CD137) and increases CD137 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.